- |||||||||| Fotivda (tivozanib) / AVEO, Jazz
Preclinical, Journal: Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice. (Pubmed Central) - Jan 29, 2021 Oral plasma pharmacokinetics of tivozanib was not significantly altered in these mouse strains, nor in Cyp3a knockout and CYP3A4-humanized mice. The modest effect of ABC transporters on tivozanib brain accumulation, if also true in humans, might mean that this drug is not strongly limited in its therapeutic efficacy against malignant lesions situated partly or completely behind the blood-brain barrier.
- |||||||||| CUE-101 / Cue Biopharma
Journal: CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies. (Pubmed Central) - Jan 28, 2021 P1 The modest effect of ABC transporters on tivozanib brain accumulation, if also true in humans, might mean that this drug is not strongly limited in its therapeutic efficacy against malignant lesions situated partly or completely behind the blood-brain barrier. Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E7-specific population of cytotoxic CD8T cells, a favorable safety profile, and in vitro and in vivo evidence supporting its potential for clinical efficacy in an ongoing Phase 1 trial (NCT03978689).
- |||||||||| Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial completion date, Trial primary completion date: The Effectiveness of Megadose Shinbaro Pharmacopuncture for Patients With Chronic Shoulder Pain (clinicaltrials.gov) - Jan 20, 2021 P=N/A, N=80, Recruiting, These results support further development of tivozanib combined with nivolumab as a treatment option in patients with treatment-naïve or previously treated mRCC. Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Gemiglo (gemigliptin) / Sanofi, LG Chem
Journal: Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection. (Pubmed Central) - Jan 13, 2021 These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 M viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M and MERS-CoV CL suggesting their potential to be repurposed as broad-spectrum antiviral agents.
- |||||||||| ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: P30CA023074: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 6, 2021 P2, N=74, Active, not recruiting, Consequently, Q-TWiST may be considered an alternative patient-centered measure of benefit of TIVO in these settings. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Dec 2020 --> May 2021
- |||||||||| Avastin (bevacizumab) / Roche
[VIRTUAL] Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism () - Oct 24, 2020 - Abstract #SNO2020SNO_439; The same results were recapitulated with the anti-VEGFA antibody, Avastin, and the OxPhos inhibitor could be substituted with the Enolase inhibitor HEX, with similar effects...Together, these results suggest that Angiogenesis inhibitors synergize broadly with cancer therapies targeting metabolism, allowing the realization of the full potential of these previously disappointing drugs. Our results warrant systematic combination clinical trials between angiogenesis inhibitors and established, as well as emerging anti-metabolic cancer therapies.
- |||||||||| Fotivda (tivozanib) / AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
Clinical, P3 data, Journal: Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. (Pubmed Central) - Sep 23, 2020 This extensional study of a phase 3 trial (NCT01937806) suggests that BSV treatment is efficacious and safe for long-term use in treatment-naïve and TDF-experienced patients with CHB. No abstract available
- |||||||||| tigulixostat (LC350189) / LG Chem
Trial completion, Trial primary completion date: Renal PK Study of LC350189 (clinicaltrials.gov) - Sep 19, 2020 P1, N=37, Completed, Trial completion date: May 2021 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Apr 2021 Recruiting --> Completed | Trial primary completion date: May 2020 --> Sep 2020
|